Skip to main content

Table 3 IC50 and Combination Index analysis of combination therapies on T24

From: Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer

 

IC50 (95% CI,nM)

Effect (IC50 + Palbociclib 1000 nM)

Combination Index

Axitinib

919.1 (754.8–1119)

0.63

0.67

Erdafitinib

3752 (3296–4271)

0.79

0.43

NVP-BEZ235

9.12 (6.755–12.31)

0.67

0.33

CI-1040

1661 (1225–2254)

0.87

0.2

MK2206

1260 (407.6–3897)

0.55

0.44

PIK90

1581 (908.4–2753)

0.74

0.16

Everolimus

3.501 (1.605–7.637)

0.65

0.15

Roscovitine

4815 (3094–7492)

0.81

0.72

SH-4-54

2324 (2129–2537)

0.57

2.93

Stattic

2384 (2015–2820)

0.53

0.88

Ruxolitinib

21221 (18381–24500)

0.54

3.85